Sinovac Biotech Ltd. (京科兴生物制品有限公司) released a statement clarifying the situation regarding the suspension of its most important product, the hepatitis A vaccine Healive®. The company said the Health Services Bureau of Fengtai District in Beijing suspended the use of just 83 doses of the drug. The action came after the death of a minor who had been treated with the vaccine two days previously. The company said no other adverse reactions have been reported thus far. More details...

Stock Symbol: (NYSE Alternext: SVA)